Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06424522 · ClinicalTrials.gov registry record · NA
A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients
A NA study of Rectal Carcinoma and Low Anterior Resection Syndrome, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06424522 is a NA study of Rectal Carcinoma and Low Anterior Resection Syndrome that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 80 participants, below the 31,028-participant average among 5 other Rectal Carcinoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06424522, a NA study of Rectal Carcinoma and Low Anterior Resection Syndrome, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies if a bowel management program with a retrograde rectal enema (RRE) for the treatment of low anterior resection syndrome (LARS) in rectal cancer patients is better than medical management alone. Rectal cancer treatment can include a procedure where part of the rectum with cancer is removed and the remaining part of the rectum is reconnected to the colon, this is called a low anterior resection of the rectum. LARS is a common condition that can develop after undergoing a low anterior resection of the rectum. LARS consists of any change in how the body performs defecation, the discharge of feces from the body, after undergoing a resection procedure. Patients with LARS may experience fecal urgency, incontinence, increased frequency, constipation, feelings of incomplete bowel movement, or bowel emptying difficulties. Patients may experience individual symptoms of LARS or a combination of them. A bowel management program assists patient's with identifying a specific bowel management regimen that works best for managing symptoms of LARS. A RRE consists of inserting a catheter through the anus into the rectum. The RRE is designed to assist fecal emptying. Medical management of LARS can include the use of fiber, loperamide hydrochloride, or pelvic floor physical therapy. Fiber may help relieve constipation, feelings of incomplete bowel movement, or bowel emptying difficulties. Loperamide hydrocholoride may help lessen fecal urgency, incontinence, or increased frequency. Pelvic floor physical therapy may help restore strength in the rectum possibly helping to improve symptoms of LARS. Participating in a bowel management program with a RRE may be more effective in treating LARS than medical management alone.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- PROCEDURE Physical Therapy
- DIETARY_SUPPLEMENT Dietary Fiber
- PROCEDURE Enema Administration
- DRUG Loperamide Hydrochloride
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06424522
The ClinicalTrials.gov registry entry for NCT06424522 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 31,028-participant average among 5 other Rectal Carcinoma trials with a reported enrollment target (100% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Rectal Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Questionnaire Administration is the first listed.
NCT06424522 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06424522 about?
NCT06424522 is a clinical study titled "A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients". This clinical trial studies if a bowel management program with a retrograde rectal enema (RRE) for the treatment of low anterior resection syndrome (LARS) in rectal cancer patients is better than medical management alone. Rectal cancer treatment can include a procedure where part of the rectum with ...
What is the current status of trial NCT06424522?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2026-03-01. Estimated completion is 2028-12-31.
What conditions does trial NCT06424522 study?
This clinical trial studies the following conditions: Rectal Carcinoma, Low Anterior Resection Syndrome.
What interventions are being tested in trial NCT06424522?
The interventions under investigation include: Questionnaire Administration (OTHER), Physical Therapy (PROCEDURE), Dietary Fiber (DIETARY_SUPPLEMENT), Enema Administration (PROCEDURE), Loperamide Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06424522?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06424522 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)
ACTIVE NOT RECRUITING · NA
-
Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer
RECRUITING
-
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
RECRUITING · Phase 2
-
Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy
ACTIVE NOT RECRUITING
-
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.